Результаты поиска

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.

We investigated the impact of renal impairment (RI) on the outcome in multiple myeloma (MM) patients following induction and autologous stem cell transplantation (ASCT). Among 349 patients who received a first ASCT for MM, 86 (24.6%) had RI at diagnosis, defined as estimation of glomerular filtration rate (eGFR) 2 according to the modification of diet in renal disease (MDRD) formula. Post induction reversal of renal function occurred in 68 (79%) patients including complete renal response in 37.2%. Two hundred and fifty-one patients had received novel agents for induction; posttransplant comple

Acute and Chronic Respiratory Failure in Cancer Patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Bortezomib: the evidence of its clinical impact in multiple myeloma.

INTRODUCTION: Multiple myeloma is a relatively common and incurable form of hematologic malignancy for which there is currently no single standard therapy. Bortezomib inhibits the 20S proteasome involved in the degradation of intracellular proteins, induces apoptosis, reverses drug resistance in multiple myeloma cells, and influences their microenvironment by blocking cytokine circuits, cell adhesion and angiogenesis in vivo. AIMS: The objective of this review is to evaluate the evidence for the use of bortezomib in the treatment of multiple myeloma. EVIDENCE REVIEW: In patients with relapse

Совпадение в полном тексте источника
… In addition, the management of both chronic adverse events (anemia requiring red blood cell transfusion or erythropoietin or thrombocytopenia that required platelet transfusions) was included along with acute adverse events (grade 3/4 infections, skeletal complications, hypercalcemia, central nervous …

АнтиCD38 моноколональные антитела в множестве миеломы и за ее пределами: иммунотерапевтические механизмы, зрелость улик и клиническое позиционирование.

АнтиCD38 моноколональные антитела стали центральной иммунотерапевтической платформой во множестве миэломы, где они изменили курс лечения от рецидива или рефракторного заболевания, передней терапии, интенсификации технического обслуживания и минимального управления, ориентированного на остаточные заболевания. Их успех в многочисленных миеломах также стимулировал более широкое развитие в области иммуноглобулинового светового амилоида, отдельных гематологовых магнелез и юморальных иммунных расстройств. CD38 функционирует как как поверхностная мишень, так и как эктоэнзим, связанный с метаболизмом

Management of skeletal metastases: An orthopaedic surgeon's guide.

Skeletal metastasis is a common cause of severe morbidity, reduction in quality of life (QOL) and often early mortality. Its prevalence is rising due to a higher rate of diagnosis, better systemic treatment, longer lives with the disease and higher disease burden rate. As people with cancer live longer and with rising sensitivity of body imaging and surveillance, the incidence of pathological fracture, metastatic epidural cord compression is rising and constitutes a challenge for the orthopedic surgeon to maintain their QOL. Metastatic disease is no longer a death sentence condemning patients

Совпадение в полном тексте источника
… Platelet transfusions and Fresh frozen plasma may be required to correct coagulation disorder. Preoperative tumor embolization upto 24–36 h prior to surgery particularly for very vascular lesions like metastases from kidney and thyroid cancer can reduce the bleeding and need for transfusion. …

Rapidly Progressive Merkel Cell Carcinoma with Atypical Metastatic Pattern-A Case Report and Brief Literature Review.

Background and Clinical Significance: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with increasing incidence among elderly, immunocompromised patients or individuals exposed to ultraviolet radiation. Case Presentation: We present the case of an 84-year-old Caucasian male with no history of immunosuppression, who was admitted for asthenia, dysphagia, weight loss, and generalized weakness. Clinical and imaging investigations revealed a violaceous tumor on the right arm and disseminated metastases affecting the liver, spleen, bones and lymph nodes. A liver

Post-Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation.

Post-transplant cyclophosphamide (PT-CY) remains the standard of care for graft-versus-host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations. Post-transplant bendamustine (PT-BEN) has been investigated as a biologically distinct alternative. In stringent haploidentical murine models, PT-BEN uncoupled GvHD from graft-versus-leukemia (GvL) effects through mechanisms centered on myeloid modulation and preservation of innate imm

Совпадение в полном тексте источника
… First, the PT‐BEN group demonstrated significantly accelerated hematopoietic recovery, including earlier myeloid and platelet engraftment, accompanied by reduced red blood cell and platelet transfusion requirements (Table 1 ). …

Резюме книги: ISEV2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Связанная с терапией острая миелоидная лейкемия после плазмы лейкемии: доклад по делу и литературный обзор.

С улучшением выживаемости в миеломе (ММ) связанная с терапией острая лейкемия миэлоида (t-AML) стала клинически значимой второй первичной халатностью (SPM). Мы сообщаем о случае превращения MM в T-AML после мультиагентной химиотерапии и анализируем литературу о связанных с терапией лейкемиях в MM. Мы сообщаем о случае пациента, у которого был диагностирован первичный лейкемия клеток плазмы (тип ИгГ-И, R-ISS стадия III), который достиг полной ремиссии после лечения с помощью даратумумаба, линалидомида и дексаметазона после получения режима лечения, основанного на протеатических ингибиторах. Пац

Hypophosphatasia: Clinical Clues and Management Considerations.

This case report identifies typical manifestations of a patient with hypophosphatasia, a rare genetic condition in which mutations in tissue-non-specific alkaline phosphatase (TNSALP) enzymes cause low levels of alkaline phosphatase and defective bone mineralization. It explores common diagnostic clues from the history and laboratory evaluation, which can help clinicians identify the disorder. This case introduces a 49-year-old patient with a long history of fractures and dental abnormalities who was referred to endocrinology for evaluation of osteopenia. Further review of her laboratory data

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia.

Older adults who are diagnosed with acute lymphoblastic leukemia (ALL) and are treated with chemotherapy generally have poor outcomes. Blinatumomab is a CD19/CD3 bispecific T-cell engager that has been approved for the treatment of B-cell ALL in the relapsed/refractory setting or in patients with minimal residual disease (MRD) positivity. We previously reported on a small cohort of older adults with newly diagnosed Philadelphia chromosome negative B-cell ALL who were treated with blinatumomab monotherapy in the first line setting. This is a long-term follow up of those patients and their clini

Успешное лечение пациента с множественной миеломой во время беременности: отчет по делу и обзор литературы.

Множественная миелома (ММ) в связи с беременностью является редким явлением, и консенсус отсутствует. Необходимо в срочном порядке повысить уровень информированности о расследованиях, необходимых для предполагаемого диагноза ММ во время беременности, и оптимизировать управление им. МЕТОДЫ: Случай MM, произошедший во время беременности, представлен с отдельными подробностями, включая клиническое представление, результаты лабораторных исследований, диагностический процесс, курс по естественным заболеваниям, терапевтические подходы и результаты. После этого был проведен поиск литературы, а имеющи

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies.

Chimeric antigen receptor T-cell (or CAR-T) therapy and bispecific antibodies (BsAbs) have revolutionized the treatment of hematologic malignancies, offering new options for relapsed or refractory cases. However, these therapies carry risks of early complications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and delayed issues like graft-versus-host disease (GVHD), infections, and secondary cancers. Effective management requires early diagnosis using advanced biomarkers and imaging, along with prompt interventions involving immunos

Abstracts from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego, CA, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Late Breaking Orals.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double-blind, placebo-controlled Phase III TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression-free survival versus placebo-Rd (median: 20·6 vs. 14·7 months; hazard

Совпадение в полном тексте источника
… Despite the higher incidence of grade 3/4 thrombocytopenia with IRd versus placebo‐Rd, rates of platelet transfusions (8% vs. 6%) and haemorrhage events of any grade (20% vs. 19%) were similar. …

TGF-β in hematologic malignancies: molecular functions and clinical applications.

Transforming growth factor-β (TGF-β) represents a family of multifunctional cytokines, primarily secreted by megakaryocytes, monocytes, T lymphocytes, bone marrow stromal cells, and other cell types. TGF-β plays an essential role in various physiological processes, including the regulation of cell proliferation, differentiation, apoptosis, and immune homeostasis. As a key immunoregulatory cytokine, TGF-β contributes to an immunosuppressive network within the microenvironment of hematologic malignancies by modulating the functions of both adaptive and innate immune cells. Current studies have s

Эффективность и безопасность терапии клеток CAR-T и биконкретных антител в повторной/отредактированной миеломе с повреждением ренальности: анализ пропенсиентности.

Иммунотерапия с перенаправкой Т, включая химериковую антигенную рецепторную терапию T-клеток (CAR-T) и биконкретные антитела (BSAbs), изменила лечение повторной/охлажденной миеломы (RRMMM). В то же время в ходе важнейших регистрационных испытаний, как правило, исключались пациенты с существенными почечными нарушениями (РИ), что создавало критический разрыв в данных о населении, в котором болезни почек 20-50% пациентов с диагнозом. Прямого сопоставления результатов по расчетному спектру широтной фильтрации (eGFR) для обоих вариантов не проводится.МЕТОДЫ: Мы провели ретроспективное когортное исс

Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System.

Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed haematological-malignancy care, but its dermatologic safety profile remains incompletely characterised across products and indications. Methods: We analysed 8,431,841 deduplicated FDA Adverse Event Reporting System reports from 2016 Q3 to 2026 Q1. Seven approved CAR T-cell products were identified. The primary outcome was any dermatologic adverse event, defined using the MedDRA Skin and subcutaneous tissue disorders system organ class. Secondary outcomes included broad severe cutaneous adverse reactions, narrow Stevens-

Primary causes of hospital admission in HTLV-1 infected patients: infectious complications, predictors of mortality and long-term survival outcomes.

BACKGROUND: Human T-cell lymphotropic virus type 1 (HTLV-1) is a globally prevalent retrovirus associated with adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite substantial research, the high mortality risk among HTLV-1 carriers remains poorly understood. OBJECTIVE: This study aimed to identify primary causes of hospital admission, predictors of mortality, and long-term survival outcomes in HTLV-1-infected patients. METHODS: A retrospective cohort study was conducted in two referral hospitals in Mashhad, Iran, from 2011 to 2